Matthew Winton is COO at Inozyme Pharma, Inc. (INZY). They have made 2 open-market trades across 1 company since 2025, most recently 2025-11-18.
CIK 0001971400
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
2 open-market purchases totalling $117K since 2025, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| INZY | 21,743 | $87K |
| CRVO | 13,500 | $30K |
| Total | $117K |
Shares reported on the most recent Form 4, priced at the 2025-11-19 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.